4H-Chromen-4-one and quinazolin-4(3H)-one heterocycles as novel cap groups for HDAC inhibitor development

Overview

This research explores the use of 4H-chromen-4-one and quinazolin-4(3H)-one heterocycles as cap groups in the design and synthesis of novel histone deacetylase (HDAC) inhibitors. HDAC inhibitors are an important class of epigenetic drugs with applications in oncology, neurology, and inflammatory diseases. The cap group is a critical structural element that governs the selectivity and binding affinity of HDAC inhibitors toward specific HDAC isoforms. By introducing these heterocycles as cap groups, the research seeks to expand the chemical diversity available for HDAC inhibitor design and potentially improve therapeutic profiles.

The value proposition lies in offering new chemical scaffolds that can be used by pharmaceutical and biotechnology partners to develop next-generation HDAC inhibitors with enhanced selectivity and reduced off-target effects.

Technical specifications

Key features:

• Synthesis of 4H-chromen-4-one and quinazolin-4(3H)-one heterocyclic scaffolds for use as cap groups
• Application of these heterocycles in HDAC inhibitor design to modulate selectivity and activity
• Focus on rational design of cap groups to improve isoform-specific binding
• Synthetic chemistry expertise in heterocyclic compound preparation
• Foundation for structure-activity relationship (SAR) studies in HDAC inhibitor development

Technology readiness level

This research is at an early stage, focused on the synthesis and investigation of novel heterocyclic cap groups. The proposed work involves preparing these compounds and evaluating their potential as HDAC inhibitor scaffolds. Further validation through biochemical and cellular assays would be needed to confirm activity and selectivity profiles, and subsequent optimization would be required before preclinical development.